ALT This image shows three Kaplan-Meier survival curves comparing talazoparib plus enzalutamide versus placebo plus enzalutamide across different subgroups over months. Each graph represents a different subgroup: Intention-to-Treat Population, BRCA Subgroup, and Non-BRCA Subgroup. The x-axis is in months, and the y-axis represents the percentage of patients. Data points are annotated with the number of events and median imaging-based progression-free survival times.

ALT A four-panel graph illustrating the secondary efficacy end points. Panel A shows overall survival, with a line graph comparing talazoparib–enzalutamide and placebo–enzalutamide over 56 months. Panel B displays a line graph of confirmed PSA progression. Panel C features a line graph detailing subsequent antineoplastic therapy. Panel D is a bar graph depicting the objective response, with categories for complete response, partial response, stable disease, and progression, comparing both treatment groups.